MYD88 Epigenetic Repressor
Hemophagocytic lymphohistiocytosis (HLH)
Pre-clinicalActive
Key Facts
About GenexGen
GenexGen is a private, preclinical-stage biotech based in Cambridge, USA, founded in 2016. The company has pivoted from its initial gene therapy focus to a novel epigenetic platform using mRNA to deliver repressors that can durably silence key immune drivers like MYD88. This approach aims to create the first targeted therapy for the rare, fatal disease HLH, while establishing a platform with potential applications in broader inflammatory and age-related conditions. The company is backed by a mix of venture capital, foundation, and government grants.
View full company profileTherapeutic Areas
Other Hemophagocytic lymphohistiocytosis (HLH) Drugs
| Drug | Company | Phase |
|---|---|---|
| Mini-CAR for HLH | Caravan Biologix | Pre-clinical |